Cholestyramine resin for erythropoietic protoporphyria with severe hepatic disease: a case report.

8Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Erythropoietic protoporphyria (EPP) is a rare disorder of heme biosynthesis caused by mutations in the gene encoding the enzyme ferrochelatase. In EPP, deficient ferrochelatase activity leads to the excessive production and biliary excretion of protoporphyrin (PP). The major clinical features of EPP are photosensitivity and hepatobiliary disease that may progress to severe liver disease, that are caused by the toxicity of PP. EPP-related liver disease has been treated medically or surgically including liver transplantation. We described a 20-year-old male with severe liver disease who was diagnosed with EPP based on clinical and laboratory findings. He was treated with cholestyramine resin. Six months after the treatment, he was doing well without any abdominal pain or photosensitivity.

Cite

CITATION STYLE

APA

Yoo, D. J., Lee, H. C., Yu, E., Jin, Y. J., Shim, J. H., Kim, K. M., … Suh, D. J. (2010). Cholestyramine resin for erythropoietic protoporphyria with severe hepatic disease: a case report. The Korean Journal of Hepatology, 16(1), 83–88. https://doi.org/10.3350/kjhep.2010.16.1.83

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free